ArticleFrontiers in oncology2025

Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer.

Kelly Gaudian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.